title: Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes.
abstract: BACKGROUND
  Controversy exists regarding the role of high-dose therapy followed by stem-cell transplant (SCT) in the treatment of T-cell lymphoblastic lymphoma (T-LBL). We conducted an intention-to-treat analysis of the strategy of SCT as definitive treatment of T-LBL.
  
  
  METHODS
  From July 1987 to March 2005, 34 adults with T-LBL were diagnosed and treated in British Columbia. Treatment, before planned SCT, consisted of a non-Hodgkin's lymphoma (NHL)/acute lymphoblastic leukemia hybrid chemotherapy protocol (28 patients) or a standard NHL chemotherapy regimen (six patients).
  
  
  RESULTS
  Median follow-up of the 23 surviving patients is 51 months (range 13-142 months). Twenty-nine proceeded to SCT (four allogeneic, 25 autologous). For all 34 patients, 4-year overall survival (OS) and event-free survival (EFS) are 72% and 68%, respectively. For patients proceeding to SCT, the 4-year OS and EFS are 79% and 73%, respectively. All patients who received allografts are alive without disease at 38-141 months since diagnosis. For patients who received autografts, the 4-year EFS is 69%. Bone marrow involvement was a significant prognostic factor predicting for a worse survival (P = 0.02).
  
  
  CONCLUSIONS
  A treatment strategy for adults with chemosensitive T-LBL that includes planned consolidation with SCT in first response produces favorable long-term outcome.
authors.affiliation: The Leukemia/Bone Marrow Transplant Program of British Columbia, The Vancouver Hospital and Health Science Center, Division of Medical Oncology, British Columbia Cancer Agency and University of British Columbia, Canada. ksong@bccancer.bc.ca
authors.forename: K W
authors.initials: KW
authors.lastname: Song
authors.forename: M J
authors.initials: MJ
authors.lastname: Barnett
authors.forename: R D
authors.initials: RD
authors.lastname: Gascoyne
authors.forename: M
authors.initials: M
authors.lastname: Chhanabhai
authors.forename: D L
authors.initials: DL
authors.lastname: Forrest
authors.forename: D E
authors.initials: DE
authors.lastname: Hogge
authors.forename: J C
authors.initials: JC
authors.lastname: Lavoie
authors.forename: S H
authors.initials: SH
authors.lastname: Nantel
authors.forename: T J
authors.initials: TJ
authors.lastname: Nevill
authors.forename: J D
authors.initials: JD
authors.lastname: Shepherd
authors.forename: C A
authors.initials: CA
authors.lastname: Smith
authors.forename: H J
authors.initials: HJ
authors.lastname: Sutherland
authors.forename: C L
authors.initials: CL
authors.lastname: Toze
authors.forename: N J
authors.initials: NJ
authors.lastname: Voss
authors.forename: J M
authors.initials: JM
authors.lastname: Connors
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001955:British Columbia; D017024:Chemotherapy, Adjuvant; D019992:Databases as Topic; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D017410:Practice Guidelines as Topic; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D011379:Prognosis; D012008:Recurrence; D012189:Retrospective Studies; D013997:Time Factors; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D016896:Treatment Outcome